Oxford BioDynamics said it had presented data supporting the use of its bio-marker products at a conference in Washington.
The update on the EpiSwitch product was delivered during a plenary talk at the American Society of Hematology Summit on Emerging Immunotherapies for Hematologic Diseases.
Chief scientific officer Alexandre Akoulitchev presented data on prognostic blood-based stratifications of patients with a common type of Non-Hodgkin lymphoma, and on predictive bio-markers for response to treatment.
Data presented from several indications successfully demonstrated that EpiSwitch bio-markers could help identify patients that would not respond adequately to certain mono-therapies.
'Our aim is to develop and deliver non-invasive prognostic bio-markers in this fast-developing and competitive field, and we were pleased to present strong data at this ASH Summit,' Akoulitchev said.